A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

You may be eligible if

• Biopsy proven advanced cancer, for whom no better therapy exists.
• Enrollment of patients with breast cancer, lymphoma, renal cell cancer or ovarian cancer are encouraged.
• Patients with a life expectancy of at least 16 weeks, and a performance status (Karnofsky Scale) of 70% or greater. No rapidly growing disease.
• Patients with prior therapy.
• WBC greater than 3,000/mm(3) and AGC greater than 1000/mm(3); platelets greater than 100,000/mm(3).
• Creatinine clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 90 u/L; SGPT less than 100 u/L.
• Patients must sign an informed consent and have geographic accessibility to return for follow up and treatment.
• No history of brain metastases.
• No patients currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and the treatment cannot be discontinued , or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.
• No patients with a history of coronary artery disease with angina pectoris or history of congestive heart failure.
• No patients with a history of cardiac disease, other than angina pectoris or congestive heart failure, including patients with arrhythmias or conduction system abnormalities will be considered on an individual basis.
• No patients with symptomatic peripheral neuropathy (grade 2 or greater).
• No patients with a positive serology for HIV.
• No patients who are pregnant or unwilling to practice adequate contraception.
• No patients with prior bone marrow transplantation or extensive irradiation resulting in compromised bone marrow reserve.